Core Points - The Shanghai Composite Index is at 3876.54 points with a change of 0.29%, and the total trading volume of A-shares is 961.216 billion yuan [1] - A total of 158 A-shares have seen their 5-day moving average cross below the 10-day moving average, indicating potential bearish trends [1] Group 1: Stocks with Significant Moving Average Crosses - Yuanjie Technology (688498) has a 5-day moving average of 374.30 yuan, which is 2.53% lower than its 10-day moving average of 384.03 yuan, with a current price of 357.58 yuan, down 6.89% from the 10-day average [1] - Shanshan Co., Ltd. (600884) shows a 5-day moving average of 14.14 yuan, down 2.43% from its 10-day moving average of 14.49 yuan, with a current price of 13.29 yuan, down 8.28% from the 10-day average [1] - ZhiJian Electronics (301121) has a 5-day moving average of 48.75 yuan, which is 2.05% lower than its 10-day moving average of 49.78 yuan, with a current price of 46.54 yuan, down 6.50% from the 10-day average [1] Group 2: Other Notable Stocks - WuXi AppTec (603259) has a 5-day moving average of 102.27 yuan, which is 1.97% lower than its 10-day moving average of 104.33 yuan, with a current price of 98.12 yuan, down 5.95% from the 10-day average [1] - Fabon Information (300925) shows a 5-day moving average of 25.73 yuan, down 1.78% from its 10-day moving average of 26.20 yuan, with a current price of 25.13 yuan, down 4.07% from the 10-day average [1] - Loka (603829) has a 5-day moving average of 21.29 yuan, which is 1.73% lower than its 10-day moving average of 21.67 yuan, with a current price of 20.07 yuan, down 7.37% from the 10-day average [1]

Group 1 - The company *ST Sailong (SZ 002898) announced on October 10 that its 16th board meeting of the fourth session will be held on October 10, 2025, in Zhuhai, combining in-person and communication methods [1] - The meeting will review the proposal for the re-election of the chairman of the Strategic Decision-Making Committee of the fourth board [1] - As of the report, *ST Sailong has a market capitalization of 2.4 billion yuan [1] Group 2 - For the first half of 2025, the revenue composition of *ST Sailong is as follows: pharmaceutical manufacturing accounts for 59.82%, the electronics industry accounts for 39.78%, and other businesses account for 0.4% [1]

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-085 赛隆药业集团股份有限公司 关于选举董事长、副董事长、补选战略决策委员会主 任委员的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 赛隆药业集团股份有限公司（以下简称"公司"）于 2025 年 10 月 10 日召 开了第四届董事会第十六次会议，审议通过了《关于选举公司第四届董事会董事 长的议案》、《关于选举公司第四届董事会副董事长的议案》、《关于补选公司 第四届董事会战略决策委员会主任委员的议案》。具体情况如下： 一、选举董事长情况 同意选举殷惠军先生为公司第四届董事会董事长，任期自本次会议审议通过 之日起至第四届董事会任期届满之日止。 三、补选战略决策委员会主任委员情况 同意补选殷惠军先生为公司第四届董事会战略决策委员会主任委员，任期自 本次会议审议通过之日起至第四届董事会任期届满之日止。补选后的第四届董事 会战略决策委员会组成人员如下： 战略决策委员会：殷惠军（主任委员）、陈科、陈顿斐、张光扬、陈榕辉、 李童瑶。 特此公告。 赛隆药业集团股份有限公司 董事会 2025 年 1 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.: 010-50867666 传真/Fax: 010-56916450 网址/Website: www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于赛隆药业集团股份有限公司 2025 年第三次临时股东会的法律意见书 康达股会字【2025】第 0430 号 致：赛隆药业集团股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）以及《赛隆药业集团股份有限公司章程》（以下简称"《公司章程》"） 的规定，北京市康达律师事务所（以下简称"本所"）接受赛 ...

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-083 赛隆药业集团股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会无变更、取消、否决议案的情况； 2.本次股东会无变更以往股东会已通过决议的情况。 一、会议召开和出席情况 1．会议召开情况 （1）会议召开时间： 现场会议：2025 年 10 月 10 日（星期五）15:00 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 10 月 10 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深圳 证券交易所互联网投票系统进行网络投票的具体时间为 2025 年 10 月 10 日 9： 15-15：00。 （2）会议召开地点：珠海市香洲区南湾北路 31 号 2 单元 21 层公司会议室。 （3）召开方式：以现场投票、网络投票相结合的方式召开。 （4）会议召集人：公司董事会。 （5）会议主持人：由半数以上董事共同推举公司独立董事张建民先生主持 本次会议。 （ ...

赛隆药业集团股份有限公司（以下简称"公司"）第四届董事会第十六次会 议通知于 2025 年 10 月 9 日以书面方式通过专人送出、传真、电子邮件相结合的 方式送达各位董事。会议于 2025 年 10 月 10 日在珠海市香洲区南湾北路 31 号 2 单元 21 层公司会议室以现场与通讯相结合方式召开，会议应到董事 9 人，实际 出席董事 9 人，经与会董事共同推举，会议由董事殷惠军先生主持，公司高级管 理人员列席本次会议。本次会议的召集、召开和表决符合有关法律、行政法规、 其他规范性文件和《公司章程》的规定。 二、董事会会议审议情况 1.审议并通过了《关于选举公司第四届董事会董事长的议案》 殷惠军先生当选公司第四届董事会董事长。具体内容详见同日刊登于巨潮资 讯网（www.cninfo.com.cn）的《关于选举董事长、副董事长、补选战略决策委 员会主任委员的公告》（公告编号：2025-085）。 证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-084 赛隆药业集团股份有限公司 第四届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导 ...

Core Viewpoint - The recent personnel changes at Sairong Pharmaceutical have raised concerns among investors, especially following the company's poor financial performance and ongoing delisting risk due to negative net profit and low revenue [1][4]. Group 1: Personnel Changes - Sairong Pharmaceutical announced the resignation of key executives, including Chairman Chen Ke and Vice Presidents Zhang Xu and Duan Daifeng, with Chen continuing as President [2]. - This marks the second significant personnel shift within two months, following a complete board resignation due to a change in control [2][3]. - The new controlling shareholder, Hainan Yayi, has no actual controller, leading to further uncertainty in management stability [3]. Group 2: Financial Performance - In the first half of the year, Sairong Pharmaceutical reported revenue of 136 million yuan and a net loss of 14.83 million yuan, a significant decline from the previous year [1][4]. - The company faces delisting risk as it is projected to have negative net profit and revenue below 300 million yuan for the 2024 fiscal year [4]. - Sairong operates in the pharmaceutical industry, focusing on drug manufacturing and AI server business, with the latter still in its early stages [4]. Group 3: Business Operations - The company’s main business segments include pharmaceutical manufacturing, with products like Tigecycline and Agatroban, and an emerging AI server business [4]. - Sairong emphasizes the need to adapt to market competition and regulatory changes, particularly in drug procurement policies [5]. - The management plans to enhance research capabilities and optimize project selection for new drug development [5].

Core Viewpoint - Recent resignations of key executives at *ST Sailong (002898.SZ) due to work adjustments and personal career development plans, which will not affect the company's normal operations [1] Group 1: Executive Resignations - Chairman and President Chen Ke resigned from the position of Chairman and Head of the Strategic Decision-Making Committee but will continue as President, Director, and Committee Member [1] - Vice President and Secretary of the Board Zhang Xu resigned from the Vice President position but will remain as Secretary of the Board [1] - Vice President Duan Daifeng resigned from the Vice President position and will not hold any position in the company or its subsidiaries post-resignation [1] Group 2: Shareholding and Commitments - As of the announcement date, Chen Ke does not hold any company shares and has no unfulfilled commitments [1] - As of the announcement date, Zhang Xu does not hold any company shares and has no unfulfilled commitments [1] - As of the announcement date, Duan Daifeng does not hold any company shares and has no unfulfilled commitments [1] Group 3: Regulatory Compliance - The resignations of the Chairman and senior management will take effect upon delivery of their resignation reports to the Board of Directors, in accordance with relevant regulations [1]

Core Viewpoint - *ST Sailong (002898) announced the resignation of key executives, indicating potential shifts in company leadership and strategy [1] Group 1: Executive Resignations - Chairman and President Chen Ke resigned from the position of Chairman and Strategic Decision Committee Chairman due to work adjustments, but will continue as President, Director, and Committee Member [1] - Vice President and Board Secretary Zhang Xu resigned from the Vice President position for work adjustment reasons, but will remain as Board Secretary [1] - Vice President Duan Daifeng resigned from the Vice President position due to personal career development plans and will not hold any position in the company or its subsidiaries after resignation [1]

Group 1 - The company *ST Sailong announced changes in its leadership, with Mr. Chen Ke resigning as Chairman and head of the Strategic Decision Committee, Ms. Zhang Xu resigning as Vice President while continuing as Secretary of the Board, and Mr. Duan Daifeng resigning as Vice President due to personal career development plans [1] - For the first half of 2025, *ST Sailong's revenue composition is as follows: 59.82% from the pharmaceutical manufacturing industry, 39.78% from the electronics industry, and 0.4% from other businesses [1] Group 2 - As of the latest report, *ST Sailong has a market capitalization of 2.5 billion yuan [2]